News & Events

The information in our press releases should be considered accurate only as of the date of the press release. We disclaim any obligation to supplement or update the information in these press releases.

Impel NeuroPharma Announces First Patient Dosed in Phase 1 Clinical Trial of INP104 for Treatment of Acute Migraine Headache

SEATTLE, October 31, 2017 — Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS) disorders, today announced that the first patient was dosed in the recently-initiated Phase 1 clinical trial of INP104…


Impel NeuroPharma Board Announces Appointment of Jon Congleton as CEO

Seattle, WA—October 03, 2017—Impel NeuroPharma, Inc., a Seattle based biotechnology company, announced the appointment of veteran biotech executive Jon Congleton as the company’s new President and Chief Executive Officer (CEO). Impel is developing first-in-class intranasal drug treatments for central nervous…


Veteran Biotech Executive Timothy S. Nelson Joins Impel’s Board of Directors

SEATTLE March 3, 2017 — Impel NeuroPharma, a Seattle-based clinical-stage biotechnology company developing first-in-class intranasal drug treatments, announced today the appointment of Timothy S. Nelson as Independent Director of the Board of Directors. Mr. Nelson has over 20 years of…


Impel NeuroPharma Partners with Camargo Pharmaceutical Services for Development Programs

SEATTLE, Feb. 7, 2017 — Impel NeuroPharma, a Seattle-based clinical stage biotechnology company developing first-in-class intranasal drug treatments announced today that it has entered into service agreements with Camargo Pharmaceutical Services, LLC. Camargo will be providing end-to-end regulatory consulting and strategic…